These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7318877)

  • 1. Clinical pharmacology of tolmesoxide in refractory heart failure.
    O'Boyle CP; McGarry K; Fitzgerald D; Kelly JG; Horgan J; O'Malley K
    Eur J Clin Pharmacol; 1981; 21(3):169-72. PubMed ID: 7318877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of food on the pharmacokinetics and pharmacodynamics of tolmesoxide in essential hypertensives.
    Elliott HL; Meredith PA; McLean K; Hughes MA; Reid JL
    Eur J Clin Pharmacol; 1982; 21(4):287-91. PubMed ID: 7056273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous and oral tolmesoxide.
    Lloyd-Jones JG; Henson R; Nichols JD; Greenslade D; Clifford JM
    Eur J Clin Pharmacol; 1981 Jan; 19(2):119-25. PubMed ID: 7202471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamic changes in heart failure induced by a new vasodilator tolmesoxide.
    Lauwers P; Nievel JG
    Eur J Clin Pharmacol; 1982; 21(6):473-7. PubMed ID: 7075653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical pharmacology of vasodilator antihypertensive drugs.
    O'Malley K; O'Boyle C; Kelly JG; McNay JL; O'Brien ET
    Arch Int Pharmacodyn Ther; 1980; Suppl():95-103. PubMed ID: 7416880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients.
    Silas JH; Phillips FC; Freestone S; Tucker GT; Ramsay LE
    Eur J Clin Pharmacol; 1981 Jan; 19(2):113-8. PubMed ID: 7202470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of intravenous tolmesoxide in hypertensive patients.
    Scheen A; Luyckx AS; De Graeve J
    Arch Int Pharmacodyn Ther; 1981 Jun; 251(2):322-34. PubMed ID: 7025775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The haemodynamic and metabolic effects of tolmesoxide with special reference to impaired myocardial function.
    Mackenzie JE; Marshall RJ; Parratt JR
    Br J Pharmacol; 1986 Oct; 89(2):313-9. PubMed ID: 3779213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic monitoring and vasodilator therapy in acute left ventricular failure. Preliminary report on a new vasodilator, tolmesoxide.
    Mullie A; Lust P; Nievel J; Penninckx J; Vanhove L; Van Hoonacker G; Vendevelde K; Fenwick J; Coghill J
    Acta Anaesthesiol Belg; 1980; 31 Suppl():147-54. PubMed ID: 7457056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical pharmacology of tolmesoxide. A new vasodilator antihypertensive agent.
    O'Boyle CP; Laher M; O'Brien ET; O'Malley K; Kelly JG
    Eur J Clin Pharmacol; 1982; 23(2):93-7. PubMed ID: 6754385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolmesoxide, a drug that lowers blood pressure by a direct relaxant effect on vascular smooth muscle.
    Doxey JC
    Br J Pharmacol; 1978 May; 63(1):111-8. PubMed ID: 647155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The action of tolmesoxide on certain cardiovascular measurements in healthy human volunteers [proceedings].
    Buylla JA; Clifford JM; Wynne RD
    Br J Clin Pharmacol; 1979 Oct; 8(4):402P. PubMed ID: 508540
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative studies on the effects of tolmesoxide (Rx71107), a tolmesoxide metabolite (Rx71112) and nifedipine in isolated blood vessels.
    Mikkelsen E; Pedersen OL
    Br J Pharmacol; 1981 Aug; 73(4):799-805. PubMed ID: 7272582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure.
    Markus H; Cowley AJ
    Eur J Clin Pharmacol; 1991; 40(6):535-8. PubMed ID: 1884731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide.
    Lepore JJ; Maroo A; Bigatello LM; Dec GW; Zapol WM; Bloch KD; Semigran MJ
    Chest; 2005 May; 127(5):1647-53. PubMed ID: 15888841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure.
    Axelrod RJ; De Marco T; Dae M; Botvinick EH; Chatterjee K
    J Am Coll Cardiol; 1987 May; 9(5):1124-30. PubMed ID: 3571752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
    Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic action of nicorandil in chronic congestive heart failure.
    Solal AC; Jaeger P; Bouthier J; Juliard JM; Dahan M; Gourgon R
    Am J Cardiol; 1989 Jun; 63(21):44J-48J. PubMed ID: 2525325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasodilator drugs in patients with chronic ischaemic heart failure.
    Korewicki J; Kraska T; Opolski G; Ostrzycki A
    Cor Vasa; 1985; 27(5):329-36. PubMed ID: 3935374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained haemodynamic effects of felodipine in patients with chronic cardiac failure.
    Tweddel AC; Martin W; McGhie AI; Hutton I
    Br J Clin Pharmacol; 1988 Jun; 25(6):689-94. PubMed ID: 3203040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.